Moderna Inc. ($MRNA) Stock Forecast: Down 5.1% Today

What is Moderna Inc.?

Moderna Inc. (MRNA) is a biotechnology company known for its mRNA technology, particularly recognized for its COVID-19 vaccine. The stock had a bearish movement today amidst recent developments in the market.

Why is Moderna Inc. going down?

MRNA stock is down 5.1% on Mar 27, 2026 18:41

• Moderna's stock experienced a significant drop today, possibly influenced by the broader market sentiment affected by the U.S.-Iran conflict and policy deadlines.
• The internal realignment by Vanguard, resulting in 0 reported shares, might have also contributed to the downward pressure on Moderna's stock.
• Despite ongoing growth potential from strategic partnerships and promising pipelines, the stock faced short-term selling pressure, reflecting investor concerns.
• The market's negative reaction to the overall uncertainty and rising oil prices could have led to the decline in Moderna's stock, creating potential buying opportunities for investors eyeing high-quality stocks.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

What is behind Moderna stock's recent drop in value today

Moderna Inc. (MRNA) experienced a 4.91% intraday drop, trading at $50.94, despite advancing its mRNA pipeline with phase 3 data for flu-COVID and personalized cancer vaccines expected in 2026. While technical indicators show short-term selling pressure, the stock remains above its 50-day and 200-day moving averages, suggesting medium- and long-term bullish momentum. Experts offer mixed opinions, with some noting instability due to the recent decline and others emphasizing ongoing growth potential from strategic partnerships and promising pipelines.

https://tradersunion.com/news/financial-news/show/1810980-moderna-slides-4-91percent-to-usd50-94/

Vanguard realignment: Vanguard reports 0 MRNA shares (MRNA)

The Vanguard Group filed an Amendment No. 6 to a Schedule 13G/A, announcing its beneficial ownership of Moderna Inc. common stock as 0 shares (0%). This change is due to an internal realignment effective January 12, 2026, which disaggregated certain Vanguard subsidiaries, causing them to report their holdings separately. The filing was signed on March 27, 2026, by Ashley Grim, Head of Global Fund Administration.

https://www.stocktitan.net/sec-filings/MRNA/schedule-13g-a-moderna-inc-amended-passive-investment-disclosure-c125c4a25077.html

Common Warts Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Verrica Pharma, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics, KinoPharma

DelveInsight's "Common Warts Pipeline Insight, 2026" report highlights that over 5 key companies are working on 5+ common warts treatment therapies, with several emerging therapies in clinical trials. Key companies like Verrica Pharma, Nielsen BioSciences, and KinoPharma are actively developing and advancing treatments, including initiating Phase III clinical programs for VP-102 and completing enrollment for CANDIN. The report also details market opportunities driven by the rising prevalence of warts and the continuous need for innovative therapeutic approaches.

https://www.barchart.com/story/news/1007142/common-warts-pipeline-2026-therapies-under-investigation-clinical-trials-milestones-and-fda-approvals-by-delveinsight-verrica-pharma-kino-pharma-iwaki-pharma-aclaris-therapeutics-kinopharma

Azenta, 10x Genomics, PacBio, Oscar Health, and Moderna Shares Plummet, What You Need To Know

Shares of Azenta, 10x Genomics, PacBio, Oscar Health, and Moderna plummeted in afternoon trading due to escalating uncertainty from the U.S.-Iran conflict and policy deadlines by the Trump administration, causing major indices to fall. The market's negative reaction, including concerns over prolonged conflict and rising oil prices, reflected in a decline in consumer confidence. Despite the downturn, the article suggests that significant price drops can create buying opportunities for high-quality stocks.

https://markets.financialcontent.com/stocks/article/stockstory-2026-3-27-azenta-10x-genomics-pacbio-oscar-health-and-moderna-shares-plummet-what-you-need-to-know

ImmunityBio vs. Moderna: Which Biotech Has More Upside Potential?

This article compares ImmunityBio (IBRX) and Moderna (MRNA), two biotech firms, to determine which offers better investment potential. ImmunityBio relies heavily on its single marketed drug, Anktiva, while Moderna is diversifying its pipeline beyond its COVID-19 vaccine with several new product launches planned. Although both are rated Zacks Rank #3 (Hold), Moderna is deemed the safer pick due to its broader pipeline and financial stability, contrasting with ImmunityBio's single-drug reliance and recent regulatory scrutiny.

https://www.tradingview.com/news/zacks:abd3548ae094b:0-immunitybio-vs-moderna-which-biotech-has-more-upside-potential/

Trending Today

Moderna Inc. Price History

10.02.2026 - MRNA Stock was up 5.8%

• Moderna's stock surged by 6.13% to an intraday high, showcasing robust investor confidence and market demand for the company's products.
• The company's narrower-than-expected Q4 loss and sales beating estimates indicate a positive financial performance, contributing to the bullish movement.
• Strong short-term gains, including an 89.01% year-to-date increase, coupled with high institutional holdings at 80.65%, further bolster investor sentiment in Moderna.
• Eric Green's retirement at West Pharmaceutical, a key player in vaccine distribution, may have indirectly contributed to positive market sentiment towards Moderna, emphasizing the critical role of vaccine-related companies in the current economic landscape.

18.02.2026 - MRNA Stock was down 5.1%

• Moderna's stock declined by 3.77% today.
• Institutional selling pressure, specifically with one entity reducing its stake, has impacted the stock causing short-term uncertainty.
• Despite exceeding earnings expectations and receiving positive feedback on its mRNA flu vaccine from regulatory authorities, the stock is facing a downward trend due to conflicting technical indicators and expert opinions.
• Market sentiment towards Moderna remains cautious as worries about potential risks outweigh recent company achievements and progress in precision medicine.

18.02.2026 - MRNA Stock was down 5.7%

• Moderna Inc. (MRNA) encountered a downward trend in the market today, grappling with obstacles related to its pipeline projects and financial pressures.
• Factors such as decreased demand for its COVID-19 vaccine, Spikevax, and scrutiny surrounding its pipeline advancements have influenced the stock's downturn.
• Investors are reassessing the company's future prospects as Moderna transitions focus towards diverse therapies like mRNA oncology and rare diseases, causing uncertainties in the market.
• Despite holding a substantial cash reserve, notable R&D expenses, and varied efficacy outcomes in certain trials, Moderna's stock performance has been adversely affected by the challenges it is currently facing.

05.02.2026 - MRNA Stock was down 5.5%

• Moderna experienced a bearish movement possibly due to the settlement it reached with Roivant Sciences and Arbutus Biopharma, which involved significant payouts, impacting its financials negatively.
• The positive news of being a top leader among stocks on Wednesday might have been overshadowed by the impact of the settlements on Moderna's finances.
• The increase in headcount by some Massachusetts biotech companies, including Moderna, in 2025, could indicate potential operational expansions that might have been affected by the recent legal settlements.

27.02.2026 - MRNA Stock was down 6.0%

• Moderna's stock (MRNA) faced a bearish movement, potentially attributed to profit-taking following a period of strong performance.
• Despite being a key player in the biotech industry and expanding its pipeline, investors may have reacted cautiously to potential challenges in the vaccine market and broader biotech sector.
• The company's shift towards treatments for respiratory viruses, oncology, and rare diseases may not have immediately captured market optimism, contributing to the bearish movement.
• The market's trajectory could also be influenced by general sector trends or broader economic factors impacting investor sentiment towards biotech stocks.

27.02.2026 - MRNA Stock was down 5.1%

• Moderna's stock experienced a significant drop today, possibly influenced by the broader market sentiment affected by the U.S.-Iran conflict and policy deadlines.
• The internal realignment by Vanguard, resulting in 0 reported shares, might have also contributed to the downward pressure on Moderna's stock.
• Despite ongoing growth potential from strategic partnerships and promising pipelines, the stock faced short-term selling pressure, reflecting investor concerns.
• The market's negative reaction to the overall uncertainty and rising oil prices could have led to the decline in Moderna's stock, creating potential buying opportunities for investors eyeing high-quality stocks.

27.02.2026 - MRNA Stock was down 5.2%

• A realignment announcement by Vanguard of 0 MRNA shares might have created uncertainty among investors, leading to a sell-off of Moderna stock.
• The comparison between ImmunityBio and Moderna, highlighting Moderna's broader pipeline and financial stability, could have influenced investors to shift their focus towards ImmunityBio, impacting Moderna's stock price negatively.
• Despite being a leading player in the biotech sector and strategically diversifying its pipeline, Moderna's stock might have faced downward pressure due to concerns about the company's ability to sustain growth beyond its COVID-19 vaccine.
• The potential for significant growth over the next five years for Moderna might not have been enough to offset the immediate bearish sentiment surrounding the stock today.

17.02.2026 - MRNA Stock was up 5.5%

• Today's positive movement in Moderna's stock price is linked to a recent federal court decision blocking proposed changes to the U.S. vaccine policy, a move by Health Secretary Robert F. Kennedy Jr. This ruling has provided stability for Moderna amidst concerns of policy changes impacting biotech revenues.
• Noteworthy insider selling by key individuals such as Moderna President Stephen Hoge, alongside decreased stake holdings by investment entities like Militia Capital Partners LP, contrasts the company's robust financial performance. With $1.9 billion in total revenue for 2025, investor trust in Moderna remains strong.
• The introduction of IQVIA.ai, an advanced AI platform developed in partnership with NVIDIA, to enhance operational efficiency and decision-making in the life sciences domain, may have positively influenced market sentiment towards forward-thinking biotech firms like Moderna.
• Criticism directed at the FDA for inconsistent actions, particularly concerning Moderna's vaccine submissions, underscores regulatory uncertainties that could impact the company's future initiatives and market dynamics. Nonetheless, Moderna's resilience and expansion beyond COVID-related products could help mitigate potential risks.

06.02.2026 - MRNA Stock was down 10.0%

• Moderna's bearish movement today could be attributed to profit-taking by investors after a period of strong gains or concerns about the company's future growth prospects.
• The news about PepGen's muscular dystrophy drug facing FDA hold may have negatively impacted Moderna, as it highlights the regulatory challenges and uncertainties in the biotech industry.
• Additionally, the wider loss and revenue miss by D-Wave Quantum could have spooked investors in the biotech sector, leading to a broader sell-off that affected Moderna's stock price.
• Overall, the combination of regulatory hurdles, financial performance of related companies, and profit-taking behavior likely contributed to Moderna's bearish movement today.

09.02.2026 - MRNA Stock was down 5.4%

• Sienna Gestion and Quantbot Technologies LP both made significant reductions in their stakes in Moderna, Inc., indicating a lack of confidence in the company's future performance.
• Concerns about Moderna's cash burn post a costly patent settlement and insider selling have led to a cautious outlook among analysts, resulting in a "Reduce" rating and a reduced average price target.
• While the bullish options flow and the resolution of legal issues have generated some positive sentiment, uncertainty regarding regulations and the financial repercussions of the settlement are dampening the stock's performance.
• In summary, today's downward trend in Moderna's stock can be attributed to a mix of decreased investor confidence, financial issues, and regulatory uncertainties stemming from the recent patent settlement.

11.02.2026 - MRNA Stock was up 5.6%

• Reduction of stake in Moderna by 25.3% by Jefferies Financial Group initially sparked concerns regarding the company's future outlook. However, the strong bullish movement today indicates ongoing investor optimism towards Moderna's growth potential.
• Uptick in Moderna's stock following US vaccine advisors' decision not to question mRNA COVID shots could have boosted investor confidence in the company. This move reaffirms faith in mRNA technology, crucial for Moderna's vaccine innovation.
• Moderna's stock surged 6.13% to hit a day high, outperforming the S&P 500. This indicates a positive market response to the company's recent performance and its potential for future growth, despite past long-term declines.
• Favorable sentiment in the therapeutics sector, marked by companies surpassing revenue expectations, may have also contributed to the bullish movement in Moderna's stock. Investors are demonstrating increased interest in the healthcare industry overall.

12.02.2026 - MRNA Stock was down 5.1%

• The decline in Moderna's stock could be linked to profit-taking by institutional investors such as Jefferies Financial Group, which notably decreased its holdings in the company.
• Resolving patent disputes related to its COVID-19 vaccine possibly created uncertainty among investors, despite the settlement and licensing agreements in place.
• Reports of a federal vaccine advisory panel scrapping plans to scrutinize mRNA COVID shots might have raised worries about regulatory challenges or public reception of Moderna's mRNA technology.
• Analysts' consensus "Reduce" rating and apprehensions about inflated valuations likely added to the negative sentiment surrounding Moderna's stock movement.